# Study of Two Doses of GSK Biologicals' Live Attenuated HRV Vaccine (Two Different Formulations) in Healthy Infants.

> **NCT00729001** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 529 (actual)

## Conditions studied

- Infections, Rotavirus

## Interventions

- **BIOLOGICAL:** Human Rotavirus Vaccine - two different formulations
- **BIOLOGICAL:** Prevnar
- **BIOLOGICAL:** IPOL
- **BIOLOGICAL:** Infanrix
- **BIOLOGICAL:** OmniHIB
- **BIOLOGICAL:** Pentacel

## Key facts

- **NCT ID:** NCT00729001
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-11
- **Primary completion:** 2002-09
- **Final completion:** 2002-09
- **Target enrollment:** 529 (ACTUAL)
- **Last updated:** 2016-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00729001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00729001, "Study of Two Doses of GSK Biologicals' Live Attenuated HRV Vaccine (Two Different Formulations) in Healthy Infants.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00729001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*